


For Non-Clinical Research Use Only

Osteopontin



Osteopontin (OPN) is a secreted glycoprotein that was originally isolated from bone. Its molecular weights have been reported in the range of 66 kDa to 44 kDa depending on glycosylation and phosphorylation. OPN is also known to be expressed in other fluids and tissues including milk, urine, activated T cells, smooth muscle cells, kidney and some tumor cells. OPN contains an Arg-Gly-Asp (RGD) amino acid sequence. This motif is present in fibronectin, vitronectin and a variety of other extra-cellular proteins that bind members of the integrin family of cell surface receptors such as avb3, a5b1, a8b1 and avb5, and further, it is reported that the motif is involved in cell adherence, migration, growth, cancer metastasis, angiogenesis and bone resorption. It is reported that the motif which is present at N-terminal-side from thrombin-clavage site of OPN (Human; SVVYGLR) binds to a4 and a9 integrin family, and that the motif is involved in neutrophil erosion of inflammatory cell and neutrophilic migration. Recently OPN is proving to be involved in rheumatoid arthritis. It is reported that the N-terminal fragment of thrombin-clavage OPN (OPN N-half) has increased percentage of all OPN in reumathoid patients. And further, OPN was identified as a ligand for CD44, which levels correlate with aggressiveness of lymphoid tumors and invasiveness of bladder carcinoma. Its interaction does not require RGD motif of OPN. In OPN knockout mice, it has been reported that a significantly decreased level of debridement was shown. Although the distribution and expression pattern of OPN in the human body have suggested the multiple function of OPN, its function under different situations remain obscure.

Manufacturer:

Immuno-Biological Laboratories Co., Ltd.

5-1 Aramachi, Takasaki-shi, Gunma 370-0831, JAPAN TEL: 027-310-8040 FAX: 027-310-8045

E-mail: do-ibl@ibl-japan.co.jp URL: http://www.ibl-japan.co.jp





Osteopontin

Osteopontin Antibodies										
Code No.		Nar		Volu- me	IHC F/P	W/B	Remarks			
10011	Anti- Human	Osteopontin	(10A16)	Mouse IgG MoAb	200 μg	(※ MW) 0.5 μg/mL	Ο 0.5 ~ 1 μg/mL	Human Osteopontin specific. Non- cross react to mouse and rat Osteopontin.		
10191	Anti- Human	Osteopontin	(1B20)	Mouse IgG MoAb	100 μg	Ο (※ MW) 1 ~ 2 μg/mL	O 2 μg/mL	The antibody, interestingly, can stain with rat osteopontin. Can react with human osteopontin, but unknown staining is observed in erythrocytes. (This reaction cannot be seen in rat.) Cross react to rabbit plasma osteopontin.		
11108	Anti-	Osteopontin N-Half	(34E3)	Mouse IgG MoAb	100 μg	Not Tested	Ο 5 μg/mL	Specific to C-terminal of OPN N- Half (N-terminal Osteopontin fragment cleaved by thrombin). React to Human, Mouse, Rat OPN N-Half.		
18625	Anti- Human	Osteopontin	(O-17)	Rabbit IgG Affinity purify	100 μg	(※ MW) 1 ~ 2 μg/mL	Ο 2 ~ 5 μg/mL	Cross react to both recombinant and native human Osteopontin. Can react with thrombin digested form of human Osteopontin. Non- Cross react to mouse Osteopontin		
18621	Anti- Mouse	Osteopontin	(O-17)	Rabbit IgG Affinity purify	100 μg	Ο (※ MW) 1 ~ 2 μg/mL	○ 2 ~ 5 μg/mL	Cross react to both recombinant and native mouse Osteopontin. Cross react to Rat Osteopontin and non- cross react to Human Osteopontin.		
18628	Anti- Rat	Osteopontin	(O-17)	Rabbit IgG Affinity purify	100 μg	(※ MW) 1 ~ 2 μg/mL	Ο 2 μg/mL	Cross react to both recombinant and native rat Osteopontin. Can react with Rat Osteopontin thrombin digested form. Non-cross react to Human and mouse Osteopontin		

* IHC: Immunohistochemistry, *F/P: Formalin fixed paraffin embeded tissue, *W/B: Western Blotting, *MW: Microwave pre-treatment is necessary

Osteopontin ELISA Kits											
Code No.		Name		Volu- me	Assay Range	Reaction Time	Application				
27158	Human	Osteopontin	Assay Kit - IBL	96 well	5 ~ 320 ng/mL	1st Reaction, 37℃, 1Hr 2nd Reaction, 4℃, 30min	Urine, EDTA-Plasma, Supernatant of cell lines. (Can assay both native and recombinant forms)				
27258	Human	Osteopontin N-Half	Assay Kit - IBL	96 well	6.25 ~ 400 pmol/L	1st Reaction, 37℃, 1Hr 2nd Reaction, 4℃, 30min	Urine, EDTA-Plasma, Synovial fluid, Supernatant of cell lines. (Can assay both native and recombinant forms)				
27351	Mouse	Osteopontin	Assay Kit - IBL	96 well	1 ~ 64 ng/mL	1st Reaction, 37℃, 1Hr 2nd Reaction, 4℃, 30min	Urine, EDTA-Plasma, Supernatant of cell lines. (Can assay both native and recombinant forms)				
27259	Mouse	Osteopontin N-Half	Assay Kit - IBL	96 well	25 ~ 1,600 pmol/L	1st Reaction, 37℃, 1Hr 2nd Reaction, 4℃, 30min	Urine, EDTA-Plasma, Supernatant of cell lines. (Can assay both native and recombinant forms)				
27360	Rat	Osteopontin	Assay Kit - IBL	96 well	0.07 ~ 4.75 ng/mL	1st Reaction, 37℃, 1Hr 2nd Reaction, 4℃, 30min	Urine, EDTA-Plasma, Supernatant of cell lines. (Can assay both native and recombinant forms)				

- Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T, Fukuchi Y.: Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2001; 24(3):264-71.
- Gang X, Ueki K, Kon S, Maeda M, Naruse T, Nojima Y.: Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am J Kidney Dis. 2001
- : 37(2):374-9.
 Shijubo N, Uede T, Kon S, Nagata M, Abe S.: Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog. 2000; 11(2):135-46. Review. Chiba S, Rashid MM, Okamoto H, Shiraiwa H, Kon S, Maeda M, Murakami M, Inobe M, Kitabatake A, Chambers AF, Uede T.: The role of osteopontin in the development of granulomatous lesions in lung. Microbiol Immunol. 2000; 44(4):319-32.
 Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T.: Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem. 2000; 77(3):487-98.
 Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S.: Enhanced expression of osteopontin in human diabetic artery and analysis of its fructional role in accelerated atherospass.

- diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20(3):624-8.

 Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S.: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999; 160(4):1269-73.

 Yasui T, Fujita K, Hayashi Y, Ueda K, Kon S, Maeda M, Uede T, Kohri K.: Quantification of osteopontin in the urine of healthy and stone-forming men. Urol Res.
- 1999: 27(4):225-30.
- Hotta H, Kon S, Katagiri YU, Tosa N, Tsukamoto T, Chambers AF, Uede T.: Detection of various epitopes of murine osteopontin by monoclonal antibodies. Biochem Biophys Res Commun. 1999: 257(1):6-11.
- Murakami M, Takahashi Y, Isashi Y, Kon S, Jia WY, Inobe M, Abe R, Uede T.: Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells. Proc Natl Acad Sci U S A. 1996; 93(15):7838-42.
- Kenji Yurmoto, Muneaki Ishijima, Susan R. Rittling, Kunikazu Tsuji, Yoko Tsuchiya, Shigeyuki Kon, Akira Nifuji, Toshimitsu Uede, David T. Denhardt, and Masaki Noda: Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice Proc Natl Acad Sci U S A. 2002; 99:
- Kim JH, Skates SJ, Uede T, Wong Kk KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC.: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002 Apr 3;287(13):1671-9.
 Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, Rashid MM, Morimoto J, Inobe M, Shijubo N, Chambers AF, Uede T. Mapping of functional
- epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem. 2002;84(2):420-32. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D. The integrin alpha(9)beta(1) binds
- to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem. 1999 Dec 17;274(51):36328-34.